# Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

> **NCT01459718** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Transfusion-dependent β-thalassemia Patients
- Cardiac Iron Overload

## Interventions

- **DRUG:** Deferasirox
- **DRUG:** Deferoxamine (DFO)

## Key facts

- **NCT ID:** NCT01459718
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** The study terminated due to low enrollment.
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01459718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01459718, "Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01459718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*